Evidence map›Paper›PMID 31835679›Full record

ArticleMetabolites2019

Metabolomics of Small Intestine Neuroendocrine Tumors and Related Hepatic Metastases.

Alessio Imperiale, Gilles Poncet, Pietro Addeo, Elisa Ruhland, Colette Roche, Stephanie Battini, A Ercument Cicek, Marie Pierrette Chenard, Valérie Hervieu, Bernard Goichot and 3 more

Open access · goldAbstract read
In one paragraph

Article in Metabolites, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Metabolic changes in neuroendocrine neoplasms.Cellular and molecular life sciences : CMLS · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Alessio ImperialeBiophysics and Nuclear Medicine, University Hospitals of Strasbourg, 67098 Strasbourg, France.
Gilles PoncetDigestive and Oncologic Surgery, Edouard-Herriot University Hospital, Claude-Bernard Lyon 1 University, 69622 Lyon, France.ORCID 0000-0003-4169-9631
Pietro AddeoHepato-Pancreato-Biliary Surgery and Liver transplantation, University Hospitals of Strasbourg, University of Strasbourg, 67098 Strasbourg, France.
Elisa RuhlandBiophysics and Nuclear Medicine, University Hospitals of Strasbourg, 67098 Strasbourg, France.
Colette RocheINSERM U1052/CNRS UMR5286/University of Lyon, Cancer Research Center of Lyon, 69622 Lyon, France.
Stephanie BattiniMNMS Platform, University Hospitals of Strasbourg, 67098 Strasbourg, France.ORCID 0000-0003-0839-4553
A Ercument CicekComputer Engineering Department, Bilkent University, Ankara 06800, Turkey.
Marie Pierrette ChenardFaculty of Medicine, University of Strasbourg, FMTS, 67000 Strasbourg, France.
Valérie HervieuINSERM U1052/CNRS UMR5286/University of Lyon, Cancer Research Center of Lyon, 69622 Lyon, France.
Bernard GoichotFaculty of Medicine, University of Strasbourg, FMTS, 67000 Strasbourg, France.
Philippe BachellierFaculty of Medicine, University of Strasbourg, FMTS, 67000 Strasbourg, France.
Thomas WalterMedical Oncology, Edouard Herriot Hospital, Hospices Civils de Lyon, 69622 Lyon, France.
Izzie Jacques NamerBiophysics and Nuclear Medicine, University Hospitals of Strasbourg, 67098 Strasbourg, France.
Université de Strasbourg · FRUniversité Claude Bernard Lyon 1 · FRBilkent University · TRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To assess the metabolomic fingerprint of small intestine neuroendocrine tumors (SI-NETs) and related hepatic metastases, and to investigate the influence of the hepatic environment on SI-NETs metabolome. Ninety-four tissue samples, including 46 SI-NETs, 18 hepatic NET metastases and 30 normal SI and liver samples, were analyzed using 1H-magic angle spinning (HRMAS) NMR nuclear magnetic resonance (NMR) spectroscopy. Twenty-seven metabolites were identified and quantified. Differences between primary NETs vs. normal SI and primary NETs vs. hepatic metastases, were assessed. Network analysis was performed according to several clinical and pathological features. Succinate, glutathion, taurine, myoinositol and glycerophosphocholine characterized NETs. Normal SI specimens showed higher levels of alanine, creatine, ethanolamine and aspartate. PLS-DA revealed a continuum-like distribution among normal SI, G1-SI-NETs and G2-SI-NETs. The G2-SI-NET distribution was closer and clearly separated from normal SI tissue. Lower concentration of glucose, serine and glycine, and increased levels of choline-containing compounds, taurine, lactate and alanine, were found in SI-NETs with more aggressive tumors. Higher abundance of acetate, succinate, choline, phosphocholine, taurine, lactate and aspartate discriminated liver metastases from normal hepatic parenchyma. Higher levels of alanine, ethanolamine, glycerophosphocholine and glucose was found in hepatic metastases than in primary SI-NETs. The present work gives for the first time a snapshot of the metabolomic characteristics of SI-NETs, suggesting the existence of complex metabolic reality, maybe characteristic of different tumor evolution.

Indexed as

carcinoidmetabolomicsneuroendocrine tumorsNMRspectroscopy

Identifiers

PMID31835679
PMCPMC6950539
OpenAlexW2996246764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.